Evidence map›Paper›PMID 42819389›Full record

ArticleFrontiers in immunology2026

Short-term disease control with alternate-day maintenance upadacitinib in refractory Hailey-Hailey disease: a case report.

Deping Luo, Fan Yang, Zexin Zhao, Hongxia Li, Liancheng Guan

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Deping LuoThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Fan YangThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Zexin ZhaoThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Hongxia LiThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Liancheng GuanThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hailey-Hailey disease (HHD), also known as benign familial pemphigus, is a rare autosomal dominant genodermatosis characterized by recurrent erosive lesions in intertriginous areas. Previous case reports have described clinical improvement with upadacitinib, but post-response maintenance strategies remain poorly defined. We report a 62-year-old woman with a 7-year history of refractory HHD who showed marked improvement after 2 months of upadacitinib 15 mg once daily. After 6 months of daily treatment, the lesions had completely cleared and disease control was stable. The regimen was then changed to 15 mg every other day after discussion with the patient. The change was based on sustained clinical control, concern about the financial burden of continued daily treatment, and a preference to limit prolonged systemic exposure; it was not prompted by an adverse event. The patient adhered to the alternate-day schedule, did not resume daily treatment, and required no rescue or additional therapy. During the subsequent 3 months, no new or recurrent lesions were observed and no apparent adverse events occurred. This case therefore documents short-term disease control after transition to an alternate-day maintenance schedule. Given the relapsing and fluctuating course of HHD and the limited follow-up after dose reduction, the observation should not be interpreted as evidence of durable remission or long-term efficacy.

Indexed as

Heterocyclic Compounds, 3-RingPemphigus, Benign FamilialDrug Administration ScheduleFemaleHumansMiddle AgedTreatment OutcomeHeterocyclic Compounds, 3-Ringupadacitinibalternate-day dosingHailey–Hailey diseaseJanus kinase inhibitormaintenance therapyupadacitinib

Identifiers

PMID42819389
PMCPMC13624065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.